Unless we all own our shares under one giant mutual fund called investors hub then yes we are all shareholders if record.

So Ford is held by 164,000 brokers?
http://www.otcmarkets.com/stock/F/profile

The definition of shareholder is as follows: Stockholder of record is the name of an individual or entity that an issuer carries in its shareholder register as the registered holder (not necessarily the beneficial owner) of the issuer's securities. Dividends and other distributions are paid only to shareholders of record. Stockholder of record may be also called shareholder of record or holder of record or owner of record.

http://www.otcmarkets.com/stock/ELTP/profile

Correction .01% not 1%

As of June there are only 136 shareholders of record.... considering that there are 900 million shares who's holding the big chunks? Furthermore if someone is holding big chunks of the stock it won't take much news to drive this through the roof if those holders refuse to let The shares go. Think about it, if 1 million shares are traded in volume that's roughly only 1% of all the shares and so the stock price barely moves. Some positive news late December about the FDA will push this way into the 40, 50 or $.60 range..

Background info on who's representing elite with FDA :

Mr. Eugene M. Pfeifer, also known as Gene, served as a Law Partner at King & Spalding in Washington DC. Mr. Pfeifer was a Law Partner at the Burditt, Bowles & Radzius. Mr. Pfeifer has more than 45 years of regulatory and trade experience. Among his many accomplishments, he was a major participant in the development of the Drug Price Competition and Patent Term Restoration Act of 1984, and provided strategic counseling to companies affected by that statue. In addition, he has provided regulatory advice and representation on a wide variety of FDA, FTC, and DEA regulated activities, including product approval, advertising, promotion, and compliance issues. Prior to working at Burditt, Bowles and Radzius, he served for a year in the General Counsel's office of the Federal Trade Commission, where he represented the FTC in Federal Court to enjoin violations of the Federal Trade Commission Act, and served ten years in the Chief Counsel's Office at the FDA as Associated Chief Counsel for Enforcement, Associate Chief Counsel for Drugs and Deputy Chief Counsel for Regulations and Hearings. Mr. Pfeifer has been a Director at Elite Pharmaceuticals, Inc. since April 07, 2016. During his tenure at the FDA, he was the FDA's lead litigator and Appellate Court advocate, and he briefed the FDA's cases before the Supreme Court. Mr. Pfeifer is a graduate of Brown University and the Georgetown University Law Center.

The only thing that's gonna move this up or down in the near future is the PR released after the FDA meeting. Either way, both speculative movements..... balance sheets is what gives any security value. Everyone should sit tight.

Amen

Exclusivity is only granted to A new chemical entity that contains no active moiety that has been approved by FDA in any other application submitted under section 505(b) of the Act. Oxycodone isnt new chemical entity.

I'll be honest, I like the potential in ELTP, but certain things need to catalyze it.... some positive news about a sequestox agenda moving forward will do it along with a good PR , I hope it comes before end of January

"The important thing here is the impact of this operation on shareholders. It removes the risk of serious dilution, as the company can (pretty much) fund its own development program. Operating expenses (including R&D) for the three months to September 30 came in at a little over $2 million. On hand at the end of that period totaled $12.6 million. Even without the generics revenues footing the bill, and taking the $1.8 million cost of revenue into account, the company is capitalized through 2018.

https://www.insiderfinancial.com/elite-pharmaceuticals-inc-otcmktseltp-financials-reinforce-our-upside-bias/118197/

Honestly I have no detailed thoughts about any products, they are pharmaceuticals and the value is in that alone. Inventory and approved product that is sellable in this country is a money maker. Whether it's for your dog or for cancer for heart disease or for pain. The deeper their inventory lineup can go the deeper our pockets will be lined with money. I actually hope these prices hold for a couple more weeks so I can continue to add after payday!!

"We launched Phendimetrazine, Isradipine and Hydroxyzine and strengthened our current generic profile. We created infrastructure for the [Indiscernible] and built a new facility."

We haven't given any weight to the fact that they built a new facility. That's a big deal, no weak company is going to go through the effort of building a new facility, hiring more people, signing more partnership contracts, submitting 4 new ANDAs (one per quarter), and have a potential Blockbuster drug in development (sequestox first of its kind) using patented technology that can be used in other opioids. AND have an income from current generics that contributes to R&D. Just saying, I think there is a ton of upside here.

We no longer live in a secluded economy, everything is about international partnerships and worldwide distribution. Drug abuse and pill popping is rampant everywhere, the technology is potentially groundbreaking. With an expanding inventory, more available generic products, and the cost of healthcare always rising, the demand is there. Elite isn't going anywhere.

That's what I said they mentioned a meeting third week of December with the FDA will approve some option and then they will resubmit. The CEO clearly stated that they're going to move forward with trying to get a approval and he clearly stated the steps needed. They will be giving the FDA the three options that they came up with in the third week of December the FDA will either green light or red light the option, Data from the option will be resubmitted in 2017. All that is is the just of it.

Wait for the transcript buddy, nobody's buying your negativity and you clearly cannot affect the share price

Hence the term basically stated I didn't quote him I gave you the gist of it

He basically stated that when they meet with the FDA and the third week of December the FDA will choose one of the three options and then they will resubmit

I expect a nice run leading up to FDA meeting next month.

Just bought another 50k shares. Say what you will, if your not happy with CC sell and move on.

In which ya

The argument can be made that you can buy 15% more shares between .12 and .14 meaning 15% more profit if: if/when it does go up.... .02 cents doesn't seem like much but it is.

Is everyone forgetting that this is a pharmaceutical company with drugs in development? Share price is based off balance sheet and potential balance sheet upon pipeline drug approvals. We're not in various 1,2 or 3 phases, we're at the approval part. Most small cap drug companies operate above These price levels with no income or deals in the working at all. We're talking about a patented technology for opioid abuse that can be used with other drugs. I'm not saying they'll get approval, or this company is a $3 company, what I'm saying is we all shouldn't jump off the deep end because revenue is down for the quarter 7%..... it's still better all in all than last year by 18% with enough cash to get them through forecasted sequestox approval. Share price is going to take a hit, I'm sure of that, and if you feel like you need to sell then do so, I probably might sell some too, but BUY BACK IN, when you think it's gone as low as it can because there is a lot of upside here. A CRL is not a rejection, it's the FDA saying "you can get approved if you do A, B or C"...this is a stock for trading, not investing, take profits along the way and when it peaks get out. Play the game everyone and good luck to all, both pumpers and dumpers alike..lol we're all trying to make a buck

Up 18%

Been trading for years and still get anxious on report days, it's like watching the roulette wheel spin and the ball won't stop bouncing....

Let's hope AM

Nobody loses anything until they sell.... if the stock dips down low I'm not selling, reduction in share price is not a reduction in shares. I'm not anticipating great news, but I do believe we are near the bottom in value. Like I've said before I'm not an investor I'm a trader, when I see a substantial profit percentage wise I take my profit, nobody is ever going to retire off of these stocks but you could trade them all day and make a couple bucks

Most companies release bad news on Fridays after the close. I like to look at it as a sliding scale relevant of how good or bad the News is. Terrible news is released on Friday and excellent news is released on Monday or Tuesday. Considering that it's a Wednesday I would assume that there is a mix of news in The earnings report and conference call.

I'm not an investor, I'm a trader.... some trades win some lose.... if you won all the time you or I wouldn't be on this site or trading in pennies. We're talking about a stock that trades in change, more room to go up than down. If you got your life savings in any of these stocks you have a problem, I don't put in what I'm not willing to lose...and I have a closet full of shirts lol..... good luck to everyone

As much as that would be terrible, it's exactly what I would do, a pharmaceutical company that has revenues and trades at a dime? I'll take it, worst case, loose a few hundred bucks, best case make a few grand.

That's the plan

There's a bottom line here, the share price is completely and entirely irrelevant. Most people on these boards are TRADERS, not investors. I put X amount of money in hoping to take X times 5 amount of money out. Whether the share price is a penny and goes to five cents or a dollar and goes to five dollars doesn't matter...five times my original investment is five times my original investment. I do hope elite pharmaceuticals is a homerun, if it doesn't get approved it doesn't really matter to me. This company has been around for years and they do have revenues, clearly no scam here, take profits on the run up if there's good news and standby if there is no good news, there will be profit in this company if you know how to play the trading game.

Exactly

Stock price is based off balance sheet, we all have our opinions.... yes approval will make this rise on speculation of potential balance sheet but the value is in the revenues.... ELTP can only fall to its true value, which is where it sits, IMO we are at the bottom, no approval = about same share price, approval = $1.25~$1.5 share price. I'm not a professional, I don't know if approval is coming or not, I do know that there is revenue and we will see what that is in a couple of days.

No volume....

It might happen tomorrow, E*TRADE just changed the 52 week high to 4.95 in 10/2015.... it was .175 this morning

They are presenting today at some convention, might have attracted some investors.....I believe this will continue to fluctuate until release of data by end of year, then shoot up around $4 given the data is good and then closer to $12 when phase 3 is done.... huge market here but gonna take some patience. I sold around $2.25 after doubling my $$... got a buy order in for $1.50 hopefully prior to news release. If I don't get back in I'm good but you will make money here.. good luck to you

When is next CC scheduled?

If there was good news I would assume it would have been released pre-RS to possibly avoid an RS to begin with